Amedisys (NASDAQ:AMED) PT Raised to $100.00

Amedisys (NASDAQ:AMED) had its target price hoisted by Royal Bank of Canada from $97.00 to $100.00 in a research note issued to investors on Monday, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the health services provider’s stock.

Separately, StockNews.com assumed coverage on shares of Amedisys in a research note on Saturday, March 23rd. They set a buy rating on the stock. Seven equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of Hold and a consensus price target of $97.50.

Amedisys Price Performance

Amedisys stock opened at $92.46 on Monday. Amedisys has a 12-month low of $71.19 and a 12-month high of $96.44. The stock has a market capitalization of $3.02 billion, a P/E ratio of -298.25, a P/E/G ratio of 4.34 and a beta of 0.86. The firm’s 50-day moving average is $93.61 and its two-hundred day moving average is $93.60. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.05 and a quick ratio of 1.05.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, February 21st. The health services provider reported $0.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.10). Amedisys had a positive return on equity of 12.76% and a negative net margin of 0.44%. The firm had revenue of $570.79 million for the quarter, compared to analyst estimates of $566.85 million. During the same period in the prior year, the business earned $1.16 earnings per share. Amedisys’s revenue for the quarter was up 1.6% on a year-over-year basis. Equities analysts predict that Amedisys will post 4.54 earnings per share for the current year.

Institutional Investors Weigh In On Amedisys

Several hedge funds have recently modified their holdings of the stock. Nomura Holdings Inc. boosted its position in shares of Amedisys by 604.2% in the fourth quarter. Nomura Holdings Inc. now owns 49,297 shares of the health services provider’s stock worth $4,686,000 after acquiring an additional 42,297 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Amedisys by 151.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 134,510 shares of the health services provider’s stock worth $12,787,000 after acquiring an additional 81,031 shares during the last quarter. FIL Ltd acquired a new stake in shares of Amedisys in the fourth quarter worth approximately $124,085,000. GSA Capital Partners LLP acquired a new stake in shares of Amedisys in the fourth quarter worth approximately $210,000. Finally, Public Employees Retirement System of Ohio boosted its position in shares of Amedisys by 1.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 22,934 shares of the health services provider’s stock worth $2,180,000 after acquiring an additional 371 shares during the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.